P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000969584.88427.a9 |
| _version_ | 1797281582006927360 |
|---|---|
| author | Martin C. Müller Jorge Cortes Charles Chuah Daniel Deangelo Michael Deininger François Guilhot Timothy Hughes Franck Emmanuel Nicolini Javier Pinilla-Ibarz Delphine Rea Gianantonio Rosti Neil P. Shah Moshe Talpaz Vickie Lu Thihan Padukkavidana Hagop Kantarjian |
| author_facet | Martin C. Müller Jorge Cortes Charles Chuah Daniel Deangelo Michael Deininger François Guilhot Timothy Hughes Franck Emmanuel Nicolini Javier Pinilla-Ibarz Delphine Rea Gianantonio Rosti Neil P. Shah Moshe Talpaz Vickie Lu Thihan Padukkavidana Hagop Kantarjian |
| author_sort | Martin C. Müller |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:59:31Z |
| format | Article |
| id | doaj.art-eb3dd58a194242debe7a5d6162af5c8c |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:59:31Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-eb3dd58a194242debe7a5d6162af5c8c2024-03-03T03:26:12ZengWileyHemaSphere2572-92412023-08-017e88427a910.1097/01.HS9.0000969584.88427.a9202308003-00570P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATAMartin C. Müller0Jorge Cortes1Charles Chuah2Daniel Deangelo3Michael Deininger4François Guilhot5Timothy Hughes6Franck Emmanuel Nicolini7Javier Pinilla-Ibarz8Delphine Rea9Gianantonio Rosti10Neil P. Shah11Moshe Talpaz12Vickie Lu13Thihan Padukkavidana14Hagop Kantarjian151 Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany2 Georgia Cancer Center, Augusta, United States3 Singapore General Hospital, Duke-NUS Medical School, Singapore, Singapore4 Dana-Farber Cancer Institute, Boston, United States5 Versiti Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI, United States6 INSERM Centre d’Investigation Clinique 1402, CHU de Poitiers, Poitiers, France7 University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia8 Centre Léon Bérard, Lyon, France9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States10 Hôpital Saint-Louis, Paris, France11 IRST/IRCCS “Dino Amadori”, Meldola (FC), Italy12 University of California San Francisco, San Francisco, CA, United States13 Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, United States14 Takeda Development Center Americas, Inc., Lexington, MA, United States14 Takeda Development Center Americas, Inc., Lexington, MA, United States15 The University of Texas MD Anderson Cancer Center, Houston, TX, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000969584.88427.a9 |
| spellingShingle | Martin C. Müller Jorge Cortes Charles Chuah Daniel Deangelo Michael Deininger François Guilhot Timothy Hughes Franck Emmanuel Nicolini Javier Pinilla-Ibarz Delphine Rea Gianantonio Rosti Neil P. Shah Moshe Talpaz Vickie Lu Thihan Padukkavidana Hagop Kantarjian P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA HemaSphere |
| title | P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA |
| title_full | P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA |
| title_fullStr | P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA |
| title_full_unstemmed | P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA |
| title_short | P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA |
| title_sort | p670 early cytogenetic or molecular landmark response to ponatinib treatment predicts outcomes in heavily pretreated patients with chronic phase chronic myeloid leukemia in pace 5 year data |
| url | http://journals.lww.com/10.1097/01.HS9.0000969584.88427.a9 |
| work_keys_str_mv | AT martincmuller p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT jorgecortes p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT charleschuah p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT danieldeangelo p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT michaeldeininger p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT francoisguilhot p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT timothyhughes p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT franckemmanuelnicolini p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT javierpinillaibarz p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT delphinerea p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT gianantoniorosti p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT neilpshah p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT moshetalpaz p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT vickielu p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT thihanpadukkavidana p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata AT hagopkantarjian p670earlycytogeneticormolecularlandmarkresponsetoponatinibtreatmentpredictsoutcomesinheavilypretreatedpatientswithchronicphasechronicmyeloidleukemiainpace5yeardata |